Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infection
Journal
JHEP reports : innovation in hepatology
Journal Volume
6
Journal Issue
2
Date Issued
2024-02
Author(s)
Janssen, Harry L
Lim, Young-Suk
Kim, Hyung Joon
Sowah, Leonard
Tseng, Cheng-Hao
Coffin, Carla S
Elkhashab, Magdy
Ahn, Sang Hoon
Nguyen, Anh-Hoa
Chen, Diana
Wallin, Jeffrey J
Fletcher, Simon P
McDonald, Circe
Yang, Jenny C
Gaggar, Anuj
Brainard, Diana M
Fung, Scott
Kim, Yoon Jun
Chuang, Wan-Long
Brooks, Anna E
Dunbar, P Rod
Abstract
Novel finite therapies for chronic hepatitis B (CHB) are needed, since lifelong treatment is usually required with current available oral antivirals. This phase II study (NCT03615066) evaluated the safety, pharmacodynamics, and antiviral activity of selgantolimod (a Toll-like receptor 8 agonist [TLR8]) with tenofovir alafenamide (TAF).
Subjects
HBV cure; Hepatitis B virus; immunotherapy; oral antiviral; small molecule; toll-like receptor; viremic
Type
journal article